The estimated Net Worth of Charles D. Ii Goodwin is at least $2.06 Milione dollars as of 14 November 2023. Mr. Goodwin owns over 50,000 units of Apyx Medical stock worth over $113,400 and over the last 6 years he sold APYX stock worth over $0. In addition, he makes $1,945,260 as Chief Executive Officer e Director at Apyx Medical.
Sign up
Mr. Goodwin APYX stock SEC Form 4 insiders trading
Charles has made over 3 trades of the Apyx Medical stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of APYX stock worth $78,500 on 14 November 2023.
The largest trade he's ever made was buying 50,000 units of Apyx Medical stock on 14 November 2023 worth over $78,500. On average, Charles trades about 10,000 units every 142 days since 2019. As of 14 November 2023 he still owns at least 90,000 units of Apyx Medical stock.
You can see the complete history of Mr. Goodwin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Goodwin biography
Charles D. Goodwin II serves as Chief Executive Officer, Director of the Company. Mr. Goodwin is an accomplished senior executive with over 25 years of experience in the healthcare industry. Before joining Apyx Medical in December 2017, Mr. Goodwin was the Chief Executive Officer of MIS Implants Technologies, Inc., a privately held company specializing in dental implants. Prior to this position, Mr. Goodwin spent more than 11 years with Olympus/Gyrus ACMI in a variety of commercial and leadership roles of increasing responsibility. Mr. Goodwin began as a regional sales director for Gyrus in 2002 and was later promoted to Vice President of Sales, overseeing the Company’s strong commercial ramp and assisting Gyrus’ executive leadership team in the successful acquisition of American Cytoscope Makers, or “ACMI”, for $500 million in 2005. As President of Gyrus ACMI’s surgical division, Mr. Goodwin developed the company’s global distribution network and achieved average annual sales growth of 35% for three consecutive years, resulting in a promotion to President of Worldwide Sales in 2007. As President of Worldwide Sales for Gyrus ACMI, Mr. Goodwin was responsible for a global business with approximately 700 employees and was a key contributor to the successful sale of Gyrus ACMI to Olympus for $2.2 billion in 2008. Mr. Goodwin served as Group Vice President of Olympus Corporation’s global surgical energy group, where he was responsible for commercial strategy, R&D and operations for a business with more than 500 employees worldwide. Mr. Goodwin held this position for five years before joining MIS Implants Technologies, Inc. in 2014. Mr. Goodwin holds a B.A. Finance and Economics from Eastern Washington University. The Company believes Mr. Goodwin is qualified to serve as a Director given his over 25 years of experience in the medical device industry.
What is the salary of Charles Goodwin?
As the Chief Executive Officer e Director of Apyx Medical, the total compensation of Charles Goodwin at Apyx Medical is $1,945,260. There are no executives at Apyx Medical getting paid more.
How old is Charles Goodwin?
Charles Goodwin is 54, he's been the Chief Executive Officer e Director of Apyx Medical since 2017. There are 8 older and 4 younger executives at Apyx Medical. The oldest executive at Apyx Medical Corporation is Andrew Makrides, 78, who is the Independent Chairman of the Board.
What's Charles Goodwin's mailing address?
Charles's mailing address filed with the SEC is C/O APYX MEDICAL CORPORATION, 5115 ULMERTON ROAD, CLEARWATER, FL, 33760.
Insiders trading at Apyx Medical
Over the last 6 years, insiders at Apyx Medical have traded over $0 worth of Apyx Medical stock and bought 97,836 units worth $253,260 . The most active insiders traders include Stavros G. Vizirgianakis, Charles D. Ii Goodwin e Moshe Citronowicz. On average, Apyx Medical executives and independent directors trade stock every 86 days with the average trade being worth of $18,719. The most recent stock trade was executed by Matthew C Hill on 13 August 2024, trading 5,336 units of APYX stock currently worth $6,030.
What does Apyx Medical do?
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
What does Apyx Medical's logo look like?
Complete history of Mr. Goodwin stock trades at Apyx Medical
Apyx Medical executives and stock owners
Apyx Medical executives and other stock owners filed with the SEC include:
-
Charles Goodwin,
Chief Executive Officer, Director -
Todd Hornsby,
Executive Vice President -
Moshe Citronowicz,
Senior Vice President -
Tara Semb,
Chief Financial Officer, Treasurer, Secretary -
Charles D. Goodwin II,
Pres, CEO & Director -
Todd Hornsby,
Exec. VP -
Tara H. Semb,
CFO, Treasurer & Sec. -
Moshe Citronowicz,
Sr. VP -
Lawrence Waldman,
Lead Independent Director -
John Andres,
Independent Vice Chairman of the Board -
Andrew Makrides,
Independent Chairman of the Board -
Michael Geraghty,
Independent Director -
Craig Swandal,
Independent Director -
Minnie Baylor-Henry,
Independent Director -
Wendy Lauren Levine,
Director -
Matthew C Hill,
Chief Financial Officer -
Stavros G. Vizirgianakis,
Director